Nijhout HF, Reed MC, Lam S-L, Gregory JF, Shane B, Ulrich CM: A day in the life of cell metabolism
During the week of June 15, 2026, FDA issued 25 warning letters to telehealth companies over alleged false or misleading promotional claims about compounded GLP-1 productsclaims the agency views as violating the Federal Food, Drug, and Cosmetic Acts (FDCA) misbranding provisions, including Sections 502(a) and 502(n)
That, experts say, is because what matters to employers and other payers when making coverage decisions are net prices the actual prices they pay after rebates and discounts
If you're ready to see the difference that uncompromising quality makes, you can Get Started Today